Trial Information
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
Inclusion Criteria:
- Must have pathologically or cytologically confirmed advanced solid malignancy for
which there is no standard treatment exists.
- Solid malignancy that has persisted or recurred following prior therapy or advanced
solid malignancy for which docetaxel is considered an acceptable first line treatment
option:
- Non-Small Cell Lung
- Breast
- Head and Neck
- Esophageal
- Stomach
- Ovarian carcinomas
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- Life expectancy of at least 12 weeks.
- Must have adequate organ function
- Peripheral Neuropathy must be less than Grade 2
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Determine maximum tolerated dose (MTD) of weekly docetaxel in combination with etanercept.
Outcome Time Frame:
up to 4 years
Safety Issue:
Yes
Principal Investigator
Miguel Villalona
Investigator Role:
Principal Investigator
Investigator Affiliation:
Ohio State University
Authority:
United States: Institutional Review Board
Study ID:
OSU-0023
NCT ID:
NCT00201812
Start Date:
November 2000
Completion Date:
May 2005
Related Keywords:
- Tumors
- Advanced Solid Tumors
Name | Location |
Ohio State University Medical Center |
Columbus, Ohio 43210 |